EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The Effects of Antipsychotic Dose Reduction on Movement Disorders and Cardiometabolic Indices in Patients Remitted from a First Episode of Psychosis

Yinzhao Liu iD, Iris E Sommer, Marieke J H Begemann iD, Shiral S Gangadin iD, Benjamin I Perry, Toon A W Scheurink, Nico J M van Beveren, HAMLETT and OPHELIA Consortium, Pieter Roberto Bakker, Sanne Koops

Schizophrenia Bulletin · 2026

DOI: 10.1093/schbul/sbaf116 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Schizophrenia Bulletin, 2026. Verfasst von Yinzhao Liu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Sciences, Cognitive Neuroscience Center, University Medical Center Groningen (UMCG), University of Groningen, Groningen 9713…. Hauptthemen laut MEDLINE: Antipsychotic Agents, Psychotic Disorders, Olanzapine, Tardive Dyskinesia. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Dutch Medical Science Foundation ZonMW.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Hypothesis The extent to which tapering antipsychotic (AP) attenuates AP-related movement disorders and cardiometabolic dysfunction remains unclear. We aim to investigate the long-term effects of AP-dose reduction on these adverse effects in patients remitted from a first episode of psychosis (FEP). Study Methods We included 293 FEP participants from the HAMLETT trial. Movement disorders were assessed using the St. Hans Rating Scale (SHRS) and Barnes Akathisia Rating Scale. Cardiometabolic indices included body mass index (BMI), waist circumference, blood pressure (BP), glucose, triglycerides, and cholesterol. Linear mixed-effects models assessed longitudinal relationships between AP-dose reduction, movement disorders and cardiometabolic indices. Study Results Over an average 29-month follow-up (SD = 19), a 1 mg olanzapine equivalent dose reduction from baseline was associated with a 0.013-point decrease in Parkinsonism (95% CI, −0.019, −0.006), a potential 0.003-point decrease in tardive dyskinesia (95% CI, −0.006, −0.000) on SHRS (range 0-6), and decreases of 0.037 (0.15%) kg/m2 in BMI (95% CI, −0.059, −0.015), 0.153 (0.17%) cm in waist circumference (95% CI, −0.265, −0.037), 0.023 (0.47%) mmol/L in total cholesterol (95% CI, −0.039, −0.007), 0.018 (0.60%) mmol/L in low-density lipoprotein cholesterol (95% CI, −0.032, −0.003), and 0.021 (0.58%) mmol/L in nonhigh-density lipoprotein cholesterol (95% CI, −0.037, −0.005). We found no evidence for an association with tardive dystonia, akathisia, BP, glucose, or triglycerides. Conclusions AP-dose reduction modestly benefits AP-related Parkinsonism, weight gain, cholesterol levels and potentially tardive dyskinesia in patients after FEP over time. These benefits should be carefully weighed against the risks of relapse and suicide.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antipsychotic AgentsPsychotic DisordersOlanzapineTardive DyskinesiaDrug TaperingMovement DisordersOutcome Assessment, Health CareSchizophreniaHumansFemaleAdultMaleYoung AdultAdolescentFollow-Up StudiesCholesterol

Stichwörter der Autor:innen

antipsychotic agentsdose dependencyextrapyramidal side effectsmetabolic disturbances

Substanzen

Antipsychotic AgentsOlanzapineCholesterol

Autor:innen und Institutionen

  • Department of Biomedical Sciences, Cognitive Neuroscience Center, University Medical Center Groningen (UMCG), University of Groningen, Groningen 9713 GZ, The Netherlands.
  • Institute for Mental Health, University of Birmingham, Birmingham B15 2TT, United Kingdom.
  • Parnassia Group for Mental Health Care, The Hague 2552 KS, The Netherlands.
  • Department of Neuroscience, Erasmus Medical Centre, Rotterdam 3015 GD, The Netherlands.
  • Department of Psychiatry, Erasmus Medical Centre, Rotterdam 3015 GD, The Netherlands.
  • Arkin, Institute for Mental Health, Amsterdam 1033 NN, The Netherlands.

ORCID-Profile: Yinzhao Liu, Marieke J H Begemann, Shiral S Gangadin

Förderung

  • Dutch Medical Science Foundation ZonMW

Zitieren

APA

Liu, Y., Sommer, I. E., Begemann, M. J. H., Gangadin, S. S., Perry, B. I., Scheurink, T. A. W., van Beveren, N. J. M., HAMLETT and OPHELIA Consortium, Bakker, P. R., & Koops, S. (2026). The Effects of Antipsychotic Dose Reduction on Movement Disorders and Cardiometabolic Indices in Patients Remitted from a First Episode of Psychosis. Schizophrenia Bulletin. https://doi.org/10.1093/schbul/sbaf116

Vancouver

Liu Y, Sommer IE, Begemann MJH, Gangadin SS, Perry BI, Scheurink TAW, et al. The Effects of Antipsychotic Dose Reduction on Movement Disorders and Cardiometabolic Indices in Patients Remitted from a First Episode of Psychosis. Schizophrenia Bulletin. 2026. doi:10.1093/schbul/sbaf116

BibTeX
@article{Liu2026,
  author = {Liu, Yinzhao and Sommer, Iris E and Begemann, Marieke J H and Gangadin, Shiral S and Perry, Benjamin I and Scheurink, Toon A W and van Beveren, Nico J M and HAMLETT and OPHELIA Consortium, HAMLETT and OPHELIA Consortium and Bakker, Pieter Roberto and Koops, Sanne},
  title = {The Effects of Antipsychotic Dose Reduction on Movement Disorders and Cardiometabolic Indices in Patients Remitted from a First Episode of Psychosis},
  journal = {Schizophrenia Bulletin},
  year = {2026},
  doi = {10.1093/schbul/sbaf116}
}
Kostenlos starten →